TGF-β is known to be a main player in the processes of tumor development, metastasis and angiogenesis [1–3, 14, 27]; the TGF-β pathway has been recently associated to drug resistance [17], but very little is known about TGF-β pathway specific activation in the context of chemotherapeutic administration in colon carcinoma. The gene discussed is TGFB1; the disease is neoplasm.